Program
2nd March, Program Schedule
The workshop aims to share the knowledge about recent achivements of cancer proteogenomics and cutting-edge technologies among the researchers who are interested in the clinical applications of research. This workshop will be continued with our colleagues to promote the clinical proteogenomics. The constructive ideas and comments to improve this workshop will be welcome.
| Time |
Program & Speaker |
|
8:00-8:10 （1st March, 18:00-18:10 (EST (UTC-5)).
|
Opening Remarks Hiroyuki Mano, NCC, Japan |
|
8:10-9:40 (1st March, 18:10-19:40 (EST (UTC-5)) |
Session 1: Cancer Proteogenomics for Precision Medicine Chair, Hiroyuki Mano, NCC, Japan
International Collaboration in the Age of Precision Medicine [Cancer Moonshot Proteogenomics] Henry Rodriguez, NCI, USA
Proteogenomic analysis of longitudinal trajectory of glioblastoma evolution Jong Bae Park, NCC, Korea
Patient-derived cancer models for pharmaco-proteogenomics in rare cancers Tadashi Kondo, NCC, Japan |
| 09:40-09:50 |
Break Time
|
|
09:50-10:40 (1st March, 19:50-20:40 (EST (UTC-5)) |
Plenary session 1 Chair, Tadashi Kondo, NCC, Japan
The ProCan® pan-cancer knowledge base of proteomic and clinical data Roger Reddel, ProCan, Children's Medical Research Institute, Australia |
|
10:40-10:50 |
Break Time
|
|
10:50-11:40 (1st March, 20:50-21:40 (EST (UTC-5)) |
Plenary session 2 Chair, Koichi Ogura, NCC, Japan
Insights from routine, large scale clinical cancer genomic testing of sarcomas Marc Ladanyi, Memorial Sloan Kettering Cancer Center, USA |
|
11:40-12:00
|
Lunch Time |
|
12:00-14:30 (1st March, 22:00-00:30 (EST (UTC-5)) |
Session 2: Molecular characterization of sarcoma for clinical application Chair, Rei Noguchi, NCC, Japan
Genomic Landscape of Actionable Alterations in Bone and Soft Tissue Sarcomas: Report from the Center for Cancer Genomics and Advanced Therapeutics(C-CAT) database Koichi Ogura, NCC, Japan
Genomic characterization of sarcomas for novel therapy Koichi Matsuda, University of Tokyo, Japan
Proteogenomic profiling of myxoid liposarcoma Koji Ueda, Japanese Foundation of Cancer Research, Japan
Study of SS18-SSX fusion-independent vulnerabilities in synovial sarcoma Le Su, Jacksonville State University, USA
Molecular characterization of CIC-DUX4 sarcomas toward novel therapy Ross Okimoto, University of California San Francisco, USA |
|
14:30-14:40
|
Break Time |
|
14:40-16:10 (2nd March, 00:40-02:10 (EST (UTC-5)) |
Session 3: Technical challenge for proteogenomics Chair, Mari Masuda, NCC, Japan
Integrative proteogenomic analysis for cancer therapeutic biomarker discovery Satoshi Nishizuka, Iwate Medical University Institute for Biomedical Sciences, Japan
Comprehensive kinase activity assay providing prognostic biomarker candidates for treatments in oncology Rei Noguchi, NCC, Japan
Large-scale proteoform analysis in proteogenomics: current status and challenges Yasushi Ishihama, Kyoto University, Japan |
|
16:10-16:20 (2nd March, 02:10-02:20 (EST (UTC-5))
|
Closing remarks Tadashi Kondo, NCC, Japan
|
Organizer:
Tadashi Kondo, MD, PhD
Chief, Division of Rare Cancer Research
National Cancer Center
